Literature DB >> 33194048

Down-regulation of UL16-binding protein 3 mediated by interferon-gamma impairs immune killing in nasopharyngeal carcinoma.

Lingling Guo1,2, Yu Chen3,4,5, Jing Wang1,2, Chuanben Chen1,4,5.   

Abstract

BACKGROUND: Nasopharyngeal carcinoma (NPC) is a malignant tumor characterized by a large number of tumor-infiltrating lymphocytes and high expression of programmed death ligand-1 (PD-L1). Interferon-gamma (IFN-γ) has proven to be the strongest inducers of PD-L1. This study aims at investigating the effect of IFN-γ on the expression of natural killer group 2, member D ligands (NKG2DLs), a series of immune-activating proteins, and their further effect on immune killing in NPC.
METHODS: RNA-seq data from the Gene Expression Omnibus database was downloaded and analyzed for the correlation between IFN-γ and NKG2DLs. IHC staining of clinical biopsy samples was performed to support the correlation between IFN-γ and ULBP3. Different NPC cell lines were treated with IFN-γ (100 U/ml) and the expression of PD-L1 and ULBP3 were detected at different time points. The 5-8F cell lines with PD-L1 over-expression and ULBP3 knockout were established and the T-cell cytotoxicity assay was performed to investigate the effect of ULPB3 on cytotoxicity.
RESULTS: Correlation analysis and IHC staining showed that the expression of ULBP3 had a significant negative correlation with IFN-γ in NPC patients. The vitro assays revealed that ULBP3 can be time-dependently down-regulated by IFN-γ. The cytotoxicity of CD8+ T-cells that were co-cultured with ULBP3 knockout 5-8F cells was significantly impaired compared to wild type 5-8F cells.
CONCLUSIONS: IFN-γ can significantly down-regulate the expression of ULBP3 in NPC. And the down-regulation of ULBP3 and the up-regulation of PD-L1 are both mediated by IFN-γ and may collectively play a role in the inhibition of immune killing in NPC. AJTR
Copyright © 2020.

Entities:  

Keywords:  Immune killing; UL16-binding protein 3 (ULBP3); interferon-gamma (IFN-γ); nasopharyngeal carcinoma (NPC); programmed death ligand-1 (PD-L1)

Year:  2020        PMID: 33194048      PMCID: PMC7653630     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  46 in total

1.  Cutting edge: IFN-gamma enables APC to promote memory Th17 and abate Th1 cell development.

Authors:  Ilona Kryczek; Shuang Wei; Wenrong Gong; Xiaogong Shu; Wojciech Szeliga; Linhua Vatan; Lieping Chen; Guobin Wang; Weiping Zou
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

2.  Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274).

Authors:  Seung-Jin Lee; Byeong-Churl Jang; Soo-Woong Lee; Young-Il Yang; Seong-Il Suh; Yeong-Min Park; Sangtaek Oh; Jae-Gook Shin; Sheng Yao; Lieping Chen; In-Hak Choi
Journal:  FEBS Lett       Date:  2006-01-09       Impact factor: 4.124

3.  Pembrolizumab for the treatment of non-small-cell lung cancer.

Authors:  Edward B Garon; Naiyer A Rizvi; Rina Hui; Natasha Leighl; Ani S Balmanoukian; Joseph Paul Eder; Amita Patnaik; Charu Aggarwal; Matthew Gubens; Leora Horn; Enric Carcereny; Myung-Ju Ahn; Enriqueta Felip; Jong-Seok Lee; Matthew D Hellmann; Omid Hamid; Jonathan W Goldman; Jean-Charles Soria; Marisa Dolled-Filhart; Ruth Z Rutledge; Jin Zhang; Jared K Lunceford; Reshma Rangwala; Gregory M Lubiniecki; Charlotte Roach; Kenneth Emancipator; Leena Gandhi
Journal:  N Engl J Med       Date:  2015-04-19       Impact factor: 91.245

4.  Ovarian tumor-associated microRNA-20a decreases natural killer cell cytotoxicity by downregulating MICA/B expression.

Authors:  Jingyan Xie; Mengna Liu; Yujuan Li; Yunzhong Nie; Qiongyu Mi; Shuli Zhao
Journal:  Cell Mol Immunol       Date:  2014-05-12       Impact factor: 11.530

5.  MiR-10b downregulates the stress-induced cell surface molecule MICB, a critical ligand for cancer cell recognition by natural killer cells.

Authors:  Pinchas Tsukerman; Noam Stern-Ginossar; Chamutal Gur; Ariella Glasner; Daphna Nachmani; Yoav Bauman; Rachel Yamin; Alon Vitenshtein; Noah Stanietsky; Tomer Bar-Mag; Dikla Lankry; Ofer Mandelboim
Journal:  Cancer Res       Date:  2012-08-21       Impact factor: 12.701

6.  Opposing effects of interferon-alpha and interferon-gamma on the expression of major histocompatibility complex class I chain-related A in tumors.

Authors:  Cai Zhang; Jiafeng Niu; Jianhua Zhang; Yiping Wang; Zhixia Zhou; Jian Zhang; Zhigang Tian
Journal:  Cancer Sci       Date:  2008-04-14       Impact factor: 6.716

7.  Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis.

Authors:  Andreas Rohner; Ulrich Langenkamp; Uwe Siegler; Christian P Kalberer; Aleksandra Wodnar-Filipowicz
Journal:  Leuk Res       Date:  2007-03-27       Impact factor: 3.156

Review 8.  Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review.

Authors:  Feifei Teng; Xiangjiao Meng; Li Kong; Jinming Yu
Journal:  Cancer Lett       Date:  2017-11-16       Impact factor: 8.679

9.  A disease-linked ULBP6 polymorphism inhibits NKG2D-mediated target cell killing by enhancing the stability of NKG2D ligand binding.

Authors:  Jianmin Zuo; Carrie R Willcox; Fiyaz Mohammed; Martin Davey; Stuart Hunter; Kabir Khan; Ayman Antoun; Poonam Katakia; Joanne Croudace; Charlotte Inman; Helen Parry; David Briggs; Ram Malladi; Benjamin E Willcox; Paul Moss
Journal:  Sci Signal       Date:  2017-05-30       Impact factor: 8.192

10.  DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells.

Authors:  J P Houchins; T Yabe; C McSherry; F H Bach
Journal:  J Exp Med       Date:  1991-04-01       Impact factor: 14.307

View more
  1 in total

Review 1.  Current status and advances of immunotherapy in nasopharyngeal carcinoma.

Authors:  Jian-Ying Xu; Xiao-Li Wei; Yi-Qin Wang; Feng-Hua Wang
Journal:  Ther Adv Med Oncol       Date:  2022-05-07       Impact factor: 5.485

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.